Cydar EV Gains FDA Clearance for Revolutionary 3D Surgical Guidance Software
CAMBRIDGE, England, July 21, 2016 /PRNewswire/ --
- FDA Clears Cloud-based ‘Sat Nav for Surgeons’ Software for Sale in the US
- Cydar EV Uses High Performance Cloud Computing to Provide Surgical Guidance in Operating Rooms
- Cydar EV Already Used in UK Hospitals
The U.S. Food and Drug and Administration (FDA) has granted 510(k) clearance for the UK-based start-up Cydar’s revolutionary EV surgical guidance software, used in X-ray guided vascular surgery.
Cydar is the first company in the world using high performance cloud computing to provide surgical guidance in the operating room. At its core, fully-automatic computer vision tracks patients during X-ray guided surgery: enabling it combine diagnostic scan, planning information and real-time imaging with millimeter precision.
Capable of working with any existing X-ray system, Cydar EV provides the surgeon with a detailed 3D augmented reality view of anatomy. Early clinical studies have shown this enhanced 3D information is associated with large reductions in X-ray exposure to staff and patients, less use of kidney-toxic contrast agents and shortened procedure times.
“This FDA clearance is a crucial step in delivering our technology globally and is a great endorsement of the accuracy and robustness of our computer vision software - it’s further proof that our science works,” said leading vascular surgeon, Cydar co-founder and CEO Tom Carrell.
“There has been a lot of talk recently about the potential of cloud computing and artificial intelligence with health data and improving patient outcomes. We are excited to show that this approach can have real clinical impact. We’re looking forward to extending its applications into other fields such as cancer and orthopaedics and using machine learning to provide new insights and help refine surgical planning.”
Cydar EV is used in two prominent London hospitals - the Royal Free and Guy’s & St Thomas’ NHS Trust.
For further information contact:
Cydar Limited
Tom Carrell, Chief Executive Officer
tom.carrell@cydar.co.uk
+44 (0) 1223 778 020
http://www.cydarmedical.com
Investment Advisors
The Life Sciences Division
Alia Minhas
+44 (0) 20 3457 1073
ali@thelifesciencesdivision.com
Company history:
Founded in 2012, Cydar Limited is a private company that was spun out of Kings College London and Guy’s and St Thomas’ NHS Trust.
It has successfully completed two clinical studies and now gained regulatory approval both in the United States (FDA clearance) and Europe (CE mark).
CEO Tom Carrell and co-founder Graeme Penney (a leading imaging scientist) came up with the idea after becoming frustrated with the poor quality of the imaging technology used in the operating theatre.
The name Cydar stands for ‘Can You Do Another Registration?’ - a question Tom routinely asked Graeme while working with an early prototype in the operating theatre.
CEO background:
Tom Carrell
- 1991 graduated from the University of Cambridge Clinical School of Medicine
- 1996 qualified as a Fellow of the Royal College of Surgeons
- 1997 he was a Research Fellow of the Royal College of Surgeons
- 2004 awarded the Master of Surgery (MChir) degree by the University of Cambridge for his thesis on aortic aneurysms - since 2004 he’s been Consultant Vascular and Endovascular Surgeon at Guy’s and St Thomas’ Hospitals, where he established the complex endovascular aortic programme in 2007. This service remains one of the largest in Europe.
